Howmet Aerospace Inc vs Oruka Therapeutics Inc. Common Stock — how do they compare? Howmet Aerospace Inc trades at $218.99 (market cap $86.76B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.08B). The key difference: Howmet Aerospace Inc is far larger — about 17.1× Oruka Therapeutics Inc. Common Stock's market cap, and Howmet Aerospace Inc pays a 0.26% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Howmet Aerospace Inc for 35 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| HWM | ORKA | |
|---|---|---|
Market Cap | $86.76B | $5.08B |
Volume | 2,181,719 | 685,276 |
Sector | Industrials | Health |
52-Week High | $292.65 | $113.08 |
52-Week Low | $189.68 | $26.19 |
Typical Hold Time | 35 Days | 0 Days |
Enterprise Value | $90.86B | $4.21B |
Dividend Yield | 0.26% | — |
Signals from Pluang's Aura AI — not financial advice
Howmet Aerospace (HWM) trades at $216.84, down 1.8% today, with technical indicators showing bearish momentum despite strong fundamentals. The company demonstrates robust financial performance with 2026 revenue projected at $9.1B and net income of $1.9B, supported by consistent earnings beats. Analyst sentiment remains overwhelmingly positive with 84% buy ratings and a $328.10 consensus price target, representing 51% upside potential from current levels.
HWM presents a compelling growth opportunity driven by aerospace and defense demand, though technical weakness and valuation concerns at 46.88 P/E warrant caution. The stock faces near-term pressure but maintains strong institutional support and positive earnings trajectory, with Q3 2026 results on October 29 likely to be the next major catalyst.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.
Read more on HWM →Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →